Stockreport

Roivant Reports Financial Results for the Third Quarter Ended December 31, 2023, and Provides Business Update [Yahoo! Finance]

Roivant Sciences Ltd.  (ROIV) 
PDF Roivant completed the sale of Telavant to Roche for $7.1B with an additional $150M in cash payable upon the completion of a near-term milestone Batoclimab produced po [Read more]